Literature DB >> 15279758

Stroke in Children with Sickle Cell Disease.

Fenella J. Kirkham1, Michael R. DeBaun.   

Abstract

Children with sickle disease are at high risk for ischemic stroke and transient ischemic attacks, usually secondary to intracranial arteriopathy involving the terminal internal carotid and proximal middle cerebral and anterior cerebral arteries, which may be diagnosed using transcranial Doppler ultrasound or magnetic resonance angiography (MRA). Other central nervous system (CNS) complications include seizures and coma, which may be secondary to ischemic stroke, sinovenous thrombosis, reversible posterior leukoencephalopathy, or acute demyelination. The immediate priority after an acute CNS event is to improve cerebral oxygenation with oxygen supplementation to maintain peripheral saturation measured using pulse oximetry between 96% and 99%, and a simple transfusion of packed cells within an hour of presentation if the patient's hemoglobin is less than 10 g/dL. The patient then should have erythrocytapheresis or manual exchange to reduce the hemoglobin S percentage to below 30%. Computed tomography to exclude hemorrhage is mandatory and MR T2-weighted imaging with MRA, fat-saturated imaging of the neck (dissection), MR venography (sinovenous thrombosis), and diffusion-weighted imaging usually distinguishes between arterial ischemic stroke and the differential diagnoses. Comatose patients with widespread focal or global cerebral edema may have good functional outcome after surgical decompression. Anticoagulation may be indicated for dissection or sinovenous thrombosis and steroids for demyelination. Blood pressure should be reduced slowly if raised in patients with reversible posterior leukoencephalopathy. Seizures should be treated aggressively and electroencephalogram monitoring should be done to exclude subclinical seizures if the patient is unconscious. Hemorrhagic stroke may require craniectomy and drainage and/or management of vasospasm. Interventional neuroradiology with coils is an alternative to surgical clipping for aneurysms. For secondary prevention, regular blood transfusion to hemoglobin S of less than 30% reduces the risk of recurrent stroke from approximately 67% to approximately 10%. Hydroxyurea and phlebotomy may be used in patients who are alloimmunized. Moyamoya syndrome is a risk factor for recurrence despite prophylactic blood transfusion. Revascularization may prevent additional stroke. Bone marrow transplantation may be offered to patients with human leukocyte antigen-compatible siblings. Blood transfusion prevents stroke in patients with velocities greater than 200 cm per second on TCD; a phase III trial studying the prevention of the progression of silent infarction is being done. Emerging primary prophylaxis regimens being tested include citrulline and arginine, aspirin, and overnight oxygen supplementation. Physicians caring for children with sickle cell disease also should ensure adequate nutrition, including five servings of fruit and vegetables a day. The role of vitamin supplementation is controversial, particularly when patients must take daily penicillin prophylaxis.

Entities:  

Year:  2004        PMID: 15279758     DOI: 10.1007/s11940-996-0028-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  105 in total

1.  Prediction of adverse outcomes in children with sickle cell disease.

Authors:  S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

2.  Neurologic events after partial exchange transfusion for priapism in sickle cell disease.

Authors:  W R Rackoff; K Ohene-Frempong; S Month; J P Scott; B Neahring; A R Cohen
Journal:  J Pediatr       Date:  1992-06       Impact factor: 4.406

3.  Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis.

Authors:  P J Nietert; M R Abboud; M D Silverstein; S M Jackson
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

4.  Neurological manifestations in sickle-cell disease, with a review of the literature and emphasis on the prevalence of hemiplegia.

Authors:  B A Portnoy; J C Herion
Journal:  Ann Intern Med       Date:  1972-04       Impact factor: 25.391

5.  Occlusion of large cerebral vessels in sickle-cell anemia.

Authors:  J A Stockman; M A Nigro; M M Mishkin; F A Oski
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

6.  Optimization of folic acid, vitamin B(12), and vitamin B(6) supplements in pediatric patients with sickle cell disease.

Authors:  Fey P L van der Dijs; M Rebecca Fokkema; D A Janneke Dijck-Brouwer; Bram Niessink; Thaliet I C van der Wal; John-John B Schnog; Ashley J Duits; Fred D Muskiet; Frits A J Muskiet
Journal:  Am J Hematol       Date:  2002-04       Impact factor: 10.047

7.  Neurological 'soft' signs may identify children with sickle cell disease who are at risk for stroke.

Authors:  E Mercuri; J C Faundez; I Roberts; S Flora; H Bouza; F Cowan; J Pennock; G Bydder; L Dubowitz
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

8.  Unusual encephalopathy after acute chest syndrome in sickle cell disease: acute necrotizing encephalitis.

Authors:  Ki Hyeong Lee; Virgil C McKie; Elizabeth A Sekul; Robert J Adams; Fenwick T Nichols
Journal:  J Pediatr Hematol Oncol       Date:  2002-10       Impact factor: 1.289

9.  [Sickle cell anemia and internal cerebral vein thrombosis].

Authors:  C Di Roio; C Jourdan; A Terrier; F Artru
Journal:  Ann Fr Anesth Reanim       Date:  1997

10.  Nontraumatic fat embolism syndrome in sickle cell anemia.

Authors:  D P Horton; D M Ferriero; W C Mentzer
Journal:  Pediatr Neurol       Date:  1995-01       Impact factor: 3.372

View more
  10 in total

1.  Current therapy of sickle cell disease.

Authors:  Zakari Y Aliyu; Ashaunta R Tumblin; Gregory J Kato
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

Review 2.  Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research.

Authors:  Courtney A Lyle; Timothy J Bernard; Neil A Goldenberg
Journal:  Semin Thromb Hemost       Date:  2011-12-20       Impact factor: 4.180

Review 3.  Hypoxic adaptation during development: relation to pattern of neurological presentation and cognitive disability.

Authors:  Fenella J Kirkham; Avijit K Datta
Journal:  Dev Sci       Date:  2006-07

4.  Prevalence of and Risk Factors for Cerebral Microbleeds in Moyamoya Disease and Syndrome in the American Population.

Authors:  Nadeem I Khan; Ali A Saherwala; Mo Chen; Sepand Salehian; Hisham Salahuddin; Babu G Welch; Marco C Pinho; Ty Shang
Journal:  Cerebrovasc Dis Extra       Date:  2019-12-12

5.  Treatment and prevention of stroke in children with sickle cell disease.

Authors:  Shyamal H Mehta; Robert J Adams
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.972

Review 6.  Moyamoya Biomarkers.

Authors:  Edward R Smith
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

7.  Moyamoya disease in a Moroccan baby: a case report.

Authors:  Abdelhafid Houba; Nisrine Laaribi; Mohammed Meziane; Abdelhamid Jaafari; Khalil Abouelalaa; Mustapha Bensghir
Journal:  J Med Case Rep       Date:  2018-06-13

Review 8.  Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease.

Authors:  Brandon M Fox; Kirsten B Dorschel; Michael T Lawton; John E Wanebo
Journal:  Front Neurol       Date:  2021-09-03       Impact factor: 4.003

Review 9.  Role of brain inflammation in epileptogenesis.

Authors:  Jieun Choi; Sookyong Koh
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

Review 10.  Prevalence of Stroke in Asian Patients with Sickle Cell Anemia: A Systematic Review and Meta-Analysis.

Authors:  Sandip Kuikel; Robin Rauniyar; Sanjeev Kharel; Anil Bist; Subarna Giri; Sahil Thapaliya; Sunanda Paudel
Journal:  Neurol Res Int       Date:  2021-06-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.